CD8+ T cells, especially those with tissue‐resident or exhausted phenotypes, have emerged as strong predictors of favorable ICI responses, while those with central memory phenotypes or expressing TCF1/TCF7 play pivotal roles in sustaining anti‐tumor immunity post‐treatment. This evidence concerns the gene TCF7 and neoplasm.